DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,895,697 | +1.7% | 11,671 | -1.7% | 1.00% | +5.9% |
| Q2 2023 | $2,848,378 | -8.0% | 11,868 | -3.4% | 0.95% | -13.7% |
| Q1 2023 | $3,096,876 | -6.0% | 12,287 | -1.0% | 1.10% | -10.6% |
| Q4 2022 | $3,294,524 | +0.9% | 12,412 | -1.9% | 1.23% | -3.2% |
| Q3 2022 | $3,266,000 | -29.8% | 12,646 | -26.5% | 1.27% | -20.7% |
| Q2 2022 | $4,652,000 | -13.4% | 17,217 | -6.0% | 1.60% | -1.4% |
| Q1 2022 | $5,372,000 | -28.5% | 18,314 | -19.8% | 1.63% | -25.5% |
| Q4 2021 | $7,515,000 | +7.2% | 22,841 | -0.8% | 2.18% | +0.8% |
| Q3 2021 | $7,011,000 | +6.6% | 23,030 | -6.0% | 2.17% | +5.8% |
| Q2 2021 | $6,575,000 | +20.5% | 24,502 | +1.1% | 2.05% | +6.8% |
| Q1 2021 | $5,456,000 | +1.7% | 24,243 | +0.4% | 1.92% | +2.1% |
| Q4 2020 | $5,365,000 | +9.2% | 24,153 | +5.8% | 1.88% | -19.4% |
| Q3 2020 | $4,915,000 | +3.3% | 22,825 | -15.2% | 2.33% | -5.2% |
| Q2 2020 | $4,757,000 | +27.5% | 26,901 | -0.2% | 2.45% | +4.4% |
| Q1 2020 | $3,730,000 | -9.0% | 26,952 | +0.9% | 2.35% | +6.9% |
| Q4 2019 | $4,100,000 | +8.6% | 26,719 | +2.2% | 2.20% | -3.6% |
| Q3 2019 | $3,774,000 | +1.4% | 26,132 | +0.3% | 2.28% | -3.3% |
| Q2 2019 | $3,722,000 | +52.4% | 26,044 | +15.7% | 2.36% | +28.1% |
| Q1 2019 | $2,442,000 | -47.4% | 22,519 | -50.0% | 1.84% | -1.1% |
| Q4 2018 | $4,644,000 | +91.2% | 45,038 | +101.4% | 1.86% | +9.3% |
| Q3 2018 | $2,429,000 | +8.6% | 22,358 | -1.3% | 1.70% | -0.7% |
| Q2 2018 | $2,236,000 | -1.1% | 22,660 | -1.9% | 1.72% | -1.8% |
| Q1 2018 | $2,262,000 | +4.9% | 23,110 | -0.6% | 1.75% | +4.0% |
| Q4 2017 | $2,157,000 | +14.3% | 23,245 | +5.6% | 1.68% | +1.1% |
| Q3 2017 | $1,887,000 | +42.4% | 22,003 | +40.1% | 1.66% | +30.5% |
| Q2 2017 | $1,325,000 | -1.8% | 15,706 | -0.5% | 1.27% | -0.3% |
| Q1 2017 | $1,349,000 | -2.0% | 15,778 | -10.8% | 1.28% | +12.6% |
| Q4 2016 | $1,377,000 | -93.8% | 17,693 | +913.3% | 1.13% | -1.7% |
| Q3 2016 | $22,280,000 | +1194.6% | 1,746 | -89.8% | 1.15% | -23.3% |
| Q2 2016 | $1,721,000 | – | 17,040 | – | 1.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |